Velaglucerase alfa - Biologic Drug Details

Summary for velaglucerase alfa

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for velaglucerase alfa

Recent Clinical Trials for velaglucerase alfa

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
AVROBIO	Phase 2/Phase 3
Takeda	Phase 3
Shaare Zedek Medical Center	Phase 4

See all velaglucerase alfa clinical trials

Pharmacology for velaglucerase alfa

Established Pharmacologic Class

Hydrolytic Lysosomal Glucocerebroside-specific Enzyme

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for velaglucerase alfa Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for velaglucerase alfa Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	VPRIV	velaglucerase alfa	For Injection	022575	10,030,043	2035-04-22	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	VPRIV	velaglucerase alfa	For Injection	022575	10,059,772	2036-04-22	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	VPRIV	velaglucerase alfa	For Injection	022575	10,077,298	2033-11-28	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for velaglucerase alfa Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	VPRIV	velaglucerase alfa	For Injection	022575	10,406,278	2037-08-25	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	VPRIV	velaglucerase alfa	For Injection	022575	10,668,053	2034-05-02	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	VPRIV	velaglucerase alfa	For Injection	022575	10,675,328	2038-02-14	Patent claims search

International Patents for velaglucerase alfa

Country	Patent Number	Estimated Expiration
Japan	2019511246
Japan	5339905
Canada	2587883

Velaglucerase Alfa: Market Dynamics and Financial Trajectory

Last updated: February 15, 2026

Overview

Velaglucerase alfa is an enzyme replacement therapy (ERT) approved specifically for treating Type 1 Gaucher disease. Developed by Takeda Pharmaceutical, it received FDA approval in 2010, with subsequent approval in the European Union and other global markets. Its market positioning is influenced by competition, pricing strategies, and evolving treatment landscapes.

Market Size and Growth

The global Gaucher disease treatment market was valued at approximately USD 600 million in 2021. Velaglucerase alfa accounts for a significant share, although it competes with competitors like imiglucerase and recently introduced alternatives. The market has exhibited compound annual growth rate (CAGR) around 4% from 2018 through 2022. Factors driving growth include increased diagnosis rates, expanding indications, and ongoing adoption in emerging markets.

Competitive Positioning and Market Share

Velaglucerase alfa holds an estimated 40% within the Gaucher disease ERT segment. Its primary competitors include:

• Imiglucerase: Dominant for years, capturing roughly 45% of the market.
• Taliglucerase alfa: Estimated at 10%, approved for patients with hypersensitivity or ERT intolerance.
• Emerging therapies: Gene therapies and substrate reduction therapies (SRTs), which threaten ERT revenues.

Takeda’s strong manufacturing infrastructure and established reputation underpin velaglucerase alfa's market penetration.

Pricing and Reimbursement

Pricing varies by region. In the U.S., the wholesale acquisition cost (WAC) for velaglucerase alfa ranges from USD 580,000 to USD 650,000 annually per patient. Reimbursement largely depends on country-specific health systems, with insurance coverage in the U.S. and government reimbursement schemes in Europe and Asia.

Pricing strategies influence market penetration; Takeda maintains premium pricing justified by manufacturing costs and clinical efficacy. Sales are sensitive to reimbursement policies and access programs.

Regulatory Dynamics

Regulatory pathways facilitate market access but can impose constraints:

• US FDA granted accelerated approval for certain indications.
• EMA approval generalizes to broader geographic markets with varying reimbursement hurdles.

The availability of biosimilars varies; the expiration of patents varies, with imiglucerase patents expiring around 2025, opening the door for biosimilar competition.

Clinical and Regulatory Innovations Impacting Trajectory

Several developments influence velaglucerase alfa’s financial outlook:

• Introduction of gene therapies (e.g., startups and major pharma initiatives) aims for single-dose cures, threatening long-term ERT sales.
• Orphan drug designation extends market exclusivity, with supplementary patents expected into the late 2020s.
• Clinical trials focused on early intervention and pediatric use expand potential patient populations.

Financial Trajectory and Revenue Forecasts

Current revenues from velaglucerase alfa hover around USD 400 million annually. Forecasts suggest a moderate decline of 2-3% CAGR over the next five years due to biosimilar entry and competitive pressures. However, expansion in emerging markets and potential inclusion in broader indications could supplement revenue streams.

Takeda's revenue from velaglucerase alfa is projected to:

Year	USD Millions	Growth Rate (vs. prior year)
2022	420	—
2023	410	-2.4%
2024	400	-2.4%
2025	390	-2.5%
2026	380	-2.6%

Entry of biosimilars would accelerate revenue erosion, unless offset by increased market share or new indications.

Pipeline and Future Opportunities

Potential pipeline activities include:

• Enzyme formulations with improved biodistribution.
• Extended indications for other lysosomal storage disorders.
• Adjunct therapies aimed at enhancing efficacy.

Limited global adoption milestones, particularly in markets like China and India, could influence long-term sales.

---

Key Takeaways

• Velaglucerase alfa is a leading ERT for Gaucher disease, with an estimated 40% of the segment's market share.
• Market growth is driven by increased diagnosis and expanded indications but faces headwinds from biosimilar entrants.
• Pricing is premium, subject to reimbursement policies, influencing revenue trajectories.
• Competition from biosimilars, gene therapies, and emerging treatments forecast a decline of 2-3% annually over the next five years.
• Strategic expansion in emerging markets and pipeline innovation present future growth opportunities.

---

FAQs

1. What factors could accelerate velaglucerase alfa’s market decline?
Introduction of biosimilars post-patent expiration, regulatory approvals of gene therapies, and a shift towards oral treatments could reduce demand.

2. How will biosimilar competition impact sales?
Biosimilars are expected to enter around 2025, potentially eroding market share by 20-30% over five years unless offset by expanded indications or price adjustments.

3. Are there any regulatory barriers to biosimilar entry?
Yes. Patent litigations and regulatory approval processes vary by region but generally require extensive comparability studies and clinical trials.

4. Can velaglucerase alfa be used for indications beyond Gaucher disease?
Currently, approvals are limited to Type 1 Gaucher disease. Investigational uses for other lysosomal storage disorders are under clinical evaluation.

5. What role do emerging markets play in the future of velaglucerase alfa?
Emerging markets present growth opportunities through improved healthcare access, though pricing and reimbursement challenges exist.

---

Citations

[1] GlobalData, "Gaucher Disease Treatment Market Analysis," 2022.
[2] Takeda Pharmaceuticals, "Velaglucerase Alfa Product Information," 2023.
[3] FDA, "Velaglucerase Alfa Label," 2010.
[4] IQVIA, "Pharmaceutical Market Data," 2022.
[5] Biosimilar Development, "Patent Expiry Calendar," 2023.